ProCE Banner Activity

Phase Ib Study: Avadomide (CC-122) Plus Obinutuzumab in Relapsed/Refractory B-Cell NHL

Slideset Download
Conference Coverage
Novel chemotherapy-free combination of avadomide plus obinutuzumab tolerable and active in patients with relapsed/refractory NHL.

Released: December 12, 2017

Share

Provided by

Jointly provided by the Annenberg Center for Health Sciences at Eisenhower and Clinical Care Options, LLC
ProCE Banner

Supporters

This activity is supported by educational grants from

AbbVie

AstraZeneca

Celgene

Genentech TEXT Only

Janssen Biotech Pharmacyclics Abbvie

Jazz Pharmaceuticals Inc

Novartis Pharmaceuticals Corporation

Pharmacyclics Inc

Seagen

Takeda Oncology